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Li et al. (2002, 2004) reported that the bacteri-
cidal activity of neutrophils depends on the 
absolute neutrophil concentration in fibrin gels, 
a condition which mimics tissue environments, 
and in rabbit dermis in vivo. The findings that 
the critical neutrophil concentration (CNC) 
for controlling bacterial growth in fibrin gels 
(1–4 × 106 neutrophils/ml of gel) is similar to 
the CNC in rabbit dermis in vivo (4–8 × 106 
neutrophils/ml or /g dermis) showed that such 
gels are useful for studying neutrophil effector 
functions in tissue-like environments in vitro. 
We hypothesized that the critical concentra-
tion concept might be applicable to describing 
effector  functions  of  other  leukocytes,  for   
example,  the  cytolytic  activity  of  CD8+  T 
cells. Therefore, we examined CD8+ T cell–
mediated killing of target cells expressing a 
cognate antigen.
We selected activated CD8+ OT-1 cells as 
effector cells and SIINFEKL peptide–pulsed B16 
melanoma cells as target cells for these studies 
because both cell types and their interactions 
had been well characterized in vitro (Moore et al., 
1988; Ochalek et al., 1988; Snyder et al., 2003; 
Regoes et al., 2007) and in vivo (Dobrzanski 
et al., 2001; Regoes et al., 2007). To quantita-
tively assess OT-1 cell–mediated cytolysis of 
SIINFEKL peptide–pulsed B16 cells, we used a 
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We describe a quantitative model for assessing the cytolytic activity of antigen-specific 
CD8+ T cells in vitro and in vivo in which the concentration of antigen-specific CD8+ T cells 
determines the efficiency with which these cells kill cognate antigen–expressing melanoma 
cells in packed cell pellets, in three-dimensional collagen-fibrin gels in vitro, and in estab-
lished melanomas in vivo. In combination with a clonogenic assay for melanoma cells, 
collagen-fibrin gels are 4,500–5,500-fold more sensitive than the packed cell pellet–type 
assays generally used to measure CD8+ T cell cytolytic activity. An equation previously used 
to describe neutrophil bactericidal activity in vitro and in vivo also describes antigen-
specific CD8+ T cell–mediated cytolysis of cognate antigen-expressing melanoma cells in 
collagen-fibrin gels in vitro and in transplanted tumors in vivo. We have used this equation 
to calculate the critical concentration of antigen-specific CD8+ T cells, which is the con-
centration of these cells required to hold constant the concentration of a growing popula-
tion of cognate antigen-expressing melanoma cells. It is 3.5 × 105/ml collagen-fibrin gel 
in vitro and 3 × 106/ml or /g melanoma for previously published studies of ex vivo–
activated adoptively transferred tumor antigen–specific CD8+ T cell killing of cognate 
antigen–expressing melanoma cells in established tumors in vivo. The antigen-specific CD8+ 
T cell concentration required to kill 100% of 2 × 107/ml cognate antigen-expressing mela-
noma cells in collagen fibrin gels is ≥107/ml of gel.
© 2010 Budhu et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e224 CD8+ T cell–mediated killing of melanoma cells | Budhu et al.
Gels containing B16 cells at an initial concentration of >106 
B16 cells/ml in the absence of OT-1 cells remained intact for 
slightly >120 h. After this time, the gels began to dissolve and 
the growth rate of B16 cells slowed. B16 cells, like many other 
mouse and human tumor cells, secrete proteases which are 
likely responsible for gel dissolution (Baramova et al., 1994; 
Hofmann et al., 2005; Huang et al., 2005).
The concentration of SIINFEKL peptide required for optimal 
killing of B16 cells by OT-1 cells
Display of the ovalbumin peptide SIINFEKL (ova residues 
257–264) in the context of B16 MHC I (H-2Kb) targets B16 
cells for killing by activated OT-1 cells (Curtsinger et al., 1998; 
Moore et al., 1988). 96% of B16 cells incubated with 106 M 
SIINFEKL peptide for 2 h at 37°C were killed by 107 OT-1 
cells/ml of gel in 24 h, whereas 85, 40, and 32% of B16 cells 
treated with SIINFEKL at 109, 1010, and 1012 M, respec-
tively, were killed by these cells in the same time period (Fig. S1). 
In contrast, coincubation of 107 OT-1 cells/ml of gel with 
unpulsed B16 cells at 105/ml of gel reduced recovery of clo-
nogenic B16 cells by ≤10%, indicating a low level of nonspe-
cific killing of unpulsed B16 cells by activated OT-1 cells. 
We used B16 cells pulsed with 106 M SIINFEKL peptide in 
all subsequent experiments.
OT-1 cell concentration determines their efficiency  
in killing growing and nongrowing SIINFEKL-B16 cells  
in collagen-fibrin gels
To test whether the efficiency of OT-1 cell killing of SIIN-
FEKL-B16 cells depends on OT-1 cell concentration, we 
newly designed three-dimensional collagen-I–fibrin gel system 
and a previously described clonogenic assay for B16 mouse mel-
anoma cells (Freedman et al., 1984). We report in this paper that 
in every situation examined (i.e., individual SIINFEKL-B16 
cells and SIINFEKL-B16 cells in spheroids [Sutherland, 1988] in 
collagen-fibrin gels and SIINFEKL-B16 cells in centrifugally 
packed cell pellets), OT-1 T cell–mediated killing of SIIN-
FEKL-B16 cells was strictly dependent on OT-1 cell concentra-
tion. Moreover, we determined that a concentration of ≥107 
OT-1 cells/ml of gel is required for them to produce sterilizing 
immunity versus SIINFEKL-B16 cells in vitro and that activated 
OT-1 cells kill SIINFEKL-B16 cells 10-fold more efficiently 
in collagen-fibrin gels in vitro than ovalbumin peptide–
expressing B16 cells in tumors in vivo (Petersen et al., 2006).
RESULTS
Growth of B16 melanoma cells in collagen-fibrin gels
B16 melanoma cells embedded in collagen-I–fibrin gels at 
concentrations of 104–106/ml grow at an exponential rate and 
have a doubling time of 58 h (Fig. 1 A), which is 66–83% 
of their doubling time in vivo (Li et al., 1984). Microscopic 
observations of B16 cells maintained in these gels for 24 h 
showed mostly single B16 cells with lamellipods protruding 
in all directions (Fig. 1 B). By 72 h, many B16 cells aggre-
gated into small clusters. By 96–120 h, these clusters devel-
oped into spheroids (Sutherland, 1988), varying from 50 to 
100 µm in diameter. Each spheroid contained 100 B16 cells. 
Hematoxylin/eosin-stained frozen sections of gels containing 
single B16 cells and B16 cell spheroids revealed considerable 
matrix remodeling by these cells during culture (Fig. 1 B). 
Figure 1.  Growth of B16 mouse melanoma cells in collagen-fibrin gels. (A) Collagen-fibrin gels containing 5 × 104 (), 5 × 105 (), or 5 × 106 () 
B16 cells/ml and RPMI 1640 with 10% FBS and 5 × 105 M -ME were incubated at 37°C for 3 d. Gels were harvested daily and their content of clono-
genic B16 cells was assessed as described in Materials and methods. Data shown represent mean ± SEM of n = 3 experiments performed in duplicate.  
(B) Hematoxylin/eosin-stained frozen sections of B16 cells grown at 37°C in collagen-fibrin gels for 1, 3, and 5 d. Bar, 50 µm.JEM VOL. 207, January 18, 2010 
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Addition of -ME to the culture medium improved sur-
vival and effector activity of OT-1 cells (Cerottini et al., 1974). 
It also improved B16 cell growth in the first 24 h after their 
placement into collagen-fibrin gels. In the absence of -ME, 
B16 cells showed a small (20%) decline in number during 
their first 24 h in these gels (not depicted and Table S1). We 
used this observation to compare the efficiency of OT-1 cell 
killing of nongrowing (without -ME) versus growing (with 
-ME) B16 cells in collagen-fibrin gels. OT-1 cells killed 
approximately the same percentage of nongrowing SIINFEKL-
B16 cells as growing SIINFEKL-B16 cells (Fig. 2 B and   
Table S1). However, with nonproliferating B16 cells (without 
-ME in the medium), we observed a net reduction in B16 
cells at every OT-1 cell concentration. OT-1 cell concentra-
tion also determined the efficiency with which these cells 
killed SIINFEKL-B16 cells in two-dimensional cultures (un-
published data). Thus, in both two- and three-dimensional 
cultures, OT-1 cell concentration was the critical determi-
nant of killing of SIINFEKL-B16 cells.
The OT-1 critical T-cell concentration (CTC)
As noted in the Introduction, the CNC is the concentration 
of neutrophils required to hold constant the concentration of 
growing bacteria. We hypothesized that the critical concen-
tration concept also applies to OT-1 cell killing of SIINFEKL-
B16 cells. Indeed, inspection of Fig. 2 A shows that the CTC 
for killing SIINFEKL-B16 cells lies between 105 and 106 
OT-1 cells/ml collagen-fibrin gel. 105 OT-1 cells/ml of gel 
killed SIINFEKL-B16 cells at a slightly slower rate than the 
rate of B16 cell growth, whereas 106 OT-1 cells/ml killed 
SIINFEKL-B16 cells at a substantially higher rate than B16 
cell growth (Fig. 2 A). Additional experiments (unpublished 
data) showed that 3–4 × 105 OT-1 cells/ml of gel were re-
quired to hold SIINFEKL-B16 melanoma cell concentration 
constant. Therefore, the experimentally determined CTC for 
OT-1 cell killing of SIINFEKL-B16 cells is 3.5 × 105 OT-1 
cells/ml of gel.
Naive T cells from wild-type C57BL/6 mouse spleen had no 
effect on the efficiency with which OT-1 cells killed 
SIINFEKL peptide-pulsed B16 cells
It was possible that nutrient deprivation by high concentra-
tions (i.e., ≥107 cells/ml) of OT-1 cells was responsible for 
B16 cell killing. To test this possibility, we incubated 106 
SIINFEKL-B16 cells/ml of gel with 104–106 OT-1 cells/ml 
of gel without and with sufficient naive or mitogen-activated 
C57BL/6 lymphocytes to bring the total number of lympho-
cytes to 107/ml of gel. The presence of 107 naive or mitogen-
activated lymphocytes had no effect on viability or growth of 
106 SIINFEKL-B16 cells/ml of gel, and a 9–900-fold excess 
of naive or mitogen-activated lymphocytes in combination 
with activated OT-1 cells had no effect on the efficiency of 
OT-1 cell killing of 106 SIINFEKL-pulsed B16 cells/ml of 
gel (Table S2). Thus, killing of SIINFEKL-B16 cells coculti-
vated with high concentrations of OT-1 cells was not the re-
sult of nutrient depletion by the OT-1 cells.
examined the killing of 5 × 103–105/ml SIINFEKL-B16 cells 
by 104–107/ml of activated OT-1 cells in collagen-fibrin gels. 
Killing of SIINFEKL-B16 cells depended on OT-1 cell con-
centration and was unrelated to the effector/target cell ratio 
(Fig. 2, A and B). For example, 107 OT-1 cells/ml of gel 
killed 98% of SIINFEKL-B16 cells in 24 h, regardless of 
whether the initial B16 cell concentration was 106/ml of gel, 
which is a 10:1 ratio of OT-1/B16 cells, or 104 B16 cells/ml 
of gel, which is a 1,000:1 ratio of OT-1/B16 cells (Fig. 2 B). 
At OT-1 cell concentrations of 105/ml or less, more clono-
genic B16 cells were recovered after 24 h than were present 
in the inoculum (at time 0), even when the inoculum con-
tained only 104 B16 cells/ml of gel (Fig. 2 A), indicating that 
at OT-1 cell concentrations ≤105/ml, the rate of B16 growth 
exceeded the rate of OT-1 cell killing.
Figure 2.  OT-1 cell concentration determines the efficiency of 
killing of SIINFEKL-B16 cells growing in collagen-fibrin gels.  
(A) Collagen-fibrin gels containing 5 × 104 (), 5 × 105 (), or 5 × 106 
() SIINFEKL-B16 cells/ml of gel, with or without 104, 105, 106, or 107 OT-1 
cells/ml of gel, were overlaid with 0.5 ml RPMI 1640 with 10% FBS and  
5 × 105 M -ME and incubated at 37°C. Shown is the number of clono-
genic B16 cells recovered from gels at time 0 and after a 24-h incubation 
at 37°C with the indicated concentration of OT-1 cells. Data shown repre-
sent mean ± SEM of n = 3 experiments performed in duplicate. (B) Rela-
tionship between OT-1 cell concentration, initial SIINFEKL-B16 cell 
concentration, and percentage of B16 cells killed.226 CD8+ T cell–mediated killing of melanoma cells | Budhu et al.
coincubation of 106 OT-1 cells and 105 SIINFEKL-B16 cells/
ml collagen-fibrin gel in medium containing 10 or 100 nM 
concanamycin  A  (CMA),  an  inhibitor  of  vacuolar-type 
H+-ATPases (Kataoka et al., 1996) and of perforin-mediated 
killing, inhibited killing of the B16 cells by 19 and 87%, respec-
tively (Fig. S2). CMA at >100 nM was toxic to B16 cells after 
24 h (as measured by the clonogenic assay; unpublished data).
OT-1 cell concentration determines the efficiency of killing 
of SIINFEKL peptide–pulsed B16 cells in packed cell pellet–
type assays
Release of 51Cr from 51Cr-labeled target cells coincubated with 
activated CD8+ T lymphocytes in packed pellets is a standard 
technique for assessing CD8+ T lymphocyte cytolytic activity 
(Brunner et al., 1968; Martz, 1975). Target cell killing in 
these packed cell pellet–type assays is generally reported as a 
function of effector/target cell ratio. Maximal target cell kill-
ing often plateaus at <100% in these assays, even when the 
effector/target cell ratio is very high (e.g., 100:1). This pla-
teau effect is inconsistent with the concept that the extent of 
target cell killing is dependent on effector/target cell ratio. It 
is consistent, however, with a determinative role for effector 
cell concentration in target cell killing. This occurs because as 
effector cell concentration rises, it reaches close to the maximum 
effector cell concentration that can be attained in a packed 
pellet of effector cells alone. For example, the maximum con-
centration of activated OT-1 cells in a centrifugally packed 
pellet is 5.9 × 109 OT-1 cells/ml, whereas the maximum 
concentration of OT-1 cells in a packed pellet containing 
OT-1 cells and 104 B16 cells is 5 × 109 OT-1 cells/ml.
To test whether activated OT-1 cell–mediated killing of 
SIINFEKL-B16 cells in a packed cell pellet–type assay de-
pends on OT-1 cell concentration, we cosedimented varying 
numbers of activated OT-1 cells with 104 SIINFEKL-pulsed 
or nonpulsed B16 cells in wells of a 96-well plate, incubated 
them for 4 h at 37°C, and assayed the number of clonogenic 
B16 cells remaining. Virtually no unpulsed B16 cells were 
killed (Fig. 4 A). In contrast, at OT-1/B16 cell ratios between 
0.1:1 and 5:1, corresponding to OT-1 cell concentrations of 
4 × 107 and 1.5 × 109/ml, SIINFEKL-B16 cell killing increased 
in proportion to both OT-1 cells/SIINFEKL-B16 ratio and 
OT-1 cell concentration. However, at OT-1/B16 cell ratios 
of ≥5:1 there was no proportionality between the OT-1/B16 
ratio and OT-1 cell–mediated killing of B16 cells. At these 
high effector/target cell ratios, a 10-fold increase in the 
OT-1/B16 cell ratio (Fig. 4 A) produced an insignificant 
increase in B16 cytolysis (i.e., 58% killing at 5:1 and 62% kill-
ing at 50:1 [Fig. 4 A]) and only a 3.1-fold increase in OT-1 
cell concentration.
It was possible that differences in density and deformabil-
ity of B16 cells versus OT-1 cells could result in an inhomo-
geneous distribution of these cells in a cell pellet and contribute 
to the plateau effect observed in Fig. 4 A. To test this possibil-
ity, we cosedimented activated OT-1 and SIINFEKL-B16 
cells at 10:1, 50:1, and 100:1 ratios of OT-1/B16 cells, fixed 
the pellets with formalin, bisected them parallel to the axis of 
The concentration of activated OT-1 cells remains constant 
for at least 72 h of co-culture with SIINFEKL peptide–
pulsed B16 cells in collagen-fibrin gels
To determine whether the concentration of activated OT-1 
cells changed during their incubation with SIINFEKL-B16 
cells, we coincubated CFSE-labeled or unlabeled OT-1 cells 
with SIINFEKL-B16 cells in collagen-fibrin gels for 24–72 h, 
lysed the gels, and assayed the number of B16 cells and 
CFSE-labeled OT-1 cells by clonogenic assay and FACS, re-
spectively. CFSE-labeled OT-1 cells killed SIINFEKL-B16 
cells with the same efficiency as unlabeled OT-1 cells (un-
published data). FACS analysis of the CFSE-labeled cells showed 
that >90% of the OT-1 cells remained viable at 24–72 h and 
that their exposure to SIINFEKL-B16 cells in the presence or 
absence of IL-2 did not stimulate a significant number of 
them to divide (Fig. 3 A and not depicted). Control experi-
ments in which CFSE-labeled naive OT-1 splenocytes were 
incubated with SIINFEKL peptide showed dilution of the 
CFSE  label  (Fig.  3  B),  confirming  that  proliferation  of   
the CFSE-labeled cells could be detected by this assay, had 
it occurred.
Mechanism of OT-1 cell killing of peptide-pulsed B16 cells
Snyder et al. (2003) reported that activated OT-1 cell killing of 
SIINFEKL-sensitized targets is perforin dependent. Indeed, 
Figure 3.  CFSE-labeled OT-1 cells remain viable but do not divide 
when coincubated with SIINFEKL-B16 cells in collagen-fibrin gels. 
(A) 106 SIINFEKL-B16 cells/ml were coincubated with 107/ml CFSE-labeled 
OT-1 cells in collagen-fibrin gels in the presence or absence of 100 U/ml 
IL-2. Gels were lysed as described at 24, 48, and 72 h. The released cells 
were incubated in propidium iodide and analyzed by FACS. (B) CFSE-
labeled naive OT-1 splenocytes were incubated with 0.75 µg/ml SIINFEKL 
peptide at 37°C for 72 h, after which the cells were isolated and analyzed 
by FACS. Shown is a representative experiment of n = 3 experiments per-
formed in duplicate.JEM VOL. 207, January 18, 2010 
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cells and B16 cells (Ochalek et al., 1988), respectively, and 
hexagonal packing of the OT-1 cells on the surfaces of B16 
cells, we calculated that 48 OT-1 cells could bind simulta-
neously to each SIINFEKL-B16 cell. This is approximately 
ninefold in excess of the 5:1 ratio of OT-1/B16 cells that 
produces near maximal killing of SIINFEKL-B16 cells in 
packed cell pellets (Fig. 4 A). Therefore, it is unlikely that at 
very high OT-1 cell concentrations, such as those which occur 
in packed cell pellet–type assays, access to each target cell’s 
surface limits effector cell cytolytic activity.
These experiments reveal two major differences between 
OT-1 cell killing of target cells in packed cell pellet–type 
assays (Fig. 4) and in collagen-fibrin gels (Fig. 2 and Table S1). 
First, in packed cell pellet–type assays (Fig. 4) there was no 
detectable killing of SIINFEKL-B16 cells at OT-1 cell con-
centrations ≤4 × 106/ml. In contrast, OT-1 cells at 106 and 
107/ml killed 62 and 98%, respectively, of nongrowing 
(Table S1) or growing (Fig. 2) SIINFEKL-B16 cells in 24 h 
in collagen-fibrin gels. Thus, packed cell pellet–type assays may 
underestimate the cytocidal activity of CD8+ T cell popula-
tions by 70–90%. Second, packed cell pellet–type assays   
are 4,500–5,500-fold less sensitive than collagen-fibrin gel   
assays (Fig. 4 B).
To further examine the relationship between OT-1 cell 
concentration and B16 cell killing, we cosedimented a mix-
ture containing 2 × 104, 4 × 104, or 105 SIINFEKL-B16 cells, 
105 activated OT-1 cells, and sufficient naive wild-type 
C57BL/6 splenocytes to bring the total volume of cell pellets 
to 263 nl (Table S3). Under these conditions, the ratio of 
OT-1/SIINFEKL-B16  cells  rose  from  1:1  to  5:1  but  the   
OT-1 cell concentration remained constant at 3.8 × 108 OT-1 
cells/ml. At all three ratios, the percentage of SIINFEKL-B16 
cells killed was 18%. This result is consistent with those 
reported in Fig. 2 and Table S1 and confirms that OT-1 cell 
concentration determines the efficiency of OT-1 cell killing 
of SIINFEKL-B16 cells in packed cell pellet–type assays.
OT-1 cells kill SIINFEKL-B16 cells in spheroids as efficiently 
as single SIINFEKL-B16 cells
Melanoma cells, like many other tumor cells, grow in nests or 
clusters in vivo. B16 cells spontaneously form spheroids when 
cultured in suspension (Sutherland, 1988; Kuwashima et al., 
1993) or in collagen-fibrin gels for more than 3 d (Fig. 1 B). 
To assess whether the multilayering of B16 cells that occurs in 
spheroids, or in the matrix proteins which the B16 cells pro-
duce (Dewever et al., 2007), affects the sensitivity of these 
cells to OT-1 cell–mediated killing, we pulsed intact spher-
oids (100 B16 cells/spheroid) with SIINFEKL peptide, co-
incubated 103 SIINFEKL-spheroids or 105 SIINFEKL-B16 
cells dissociated from these spheroids with 106 activated OT-1 
cells for 24 and 48 h in collagen-fibrin gels, and measured the 
number of clonogenic B16 cells remaining. OT-1 cells killed 
24% more (not significant) spheroid-derived single SIIN-
FEKL-B16 cells than SIINFEKL-B16 cells in spheroids at 24 h 
(Fig. S3). At 48 h, OT-1 cells killed roughly equal percentages 
of B16 cells dissociated from spheroids (85%) and B16 cells in 
sedimentation,  sectioned  them,  stained  the  sections  with 
hematoxylin/eosin, and observed the distribution of OT-1 
and B16 cells in the pellet by light microscopy. Under all 
conditions tested, the OT-1 and B16 cells were randomly and 
uniformly distributed throughout the pellet (unpublished data). 
Thus, the observed plateau in killing is not a result of inhomo-
geneous distribution of the two cell types.
It was also possible that at very high OT-1 cell concentra-
tions these cells saturate the B16 cells’ MHC-I–SIINFEKL 
binding sites for OT-1 T cell receptors or cluster around the 
B16 cells and sterically hinder contact with them. Although 
we cannot formally exclude the former explanation, we ex-
amined the latter. Given diameters of 7 and 17.4 µm for OT-1 
Figure 4.  OT-1 cell concentration determines the efficiency of 
killing of SIINFEKL peptide–pulsed B16 cells in packed cell pellet–
type assays. (A) 104 SIINFEKL-pulsed () or nonpulsed () B16 cells were 
mixed with 10–5 × 105 activated OT-1 cells in 200 µl OT-1 medium in 
round-bottom wells of a 96-well plate. Plates were centrifuged at 50 g 
for 5 min to pellet the cells and incubated at 37°C for 4 h. Cells in each 
well were dissociated with trypsin-EDTA, and their viability was measured 
by clonogenic assay. Data shown represent mean ± SEM of n = 3 experi-
ments performed in duplicate. (B) Efficiency of OT-1 cell killing of 
SIINFEKL-B16 cells in collagen-fibrin gels () versus packed pellet–type 
assays (). Data for collagen-fibrin gels were obtained from Table S1. 
Data for packed pellet–type assays were obtained from A.228 CD8+ T cell–mediated killing of melanoma cells | Budhu et al.
Does bt    /b0 = ekpt + gt (Eq. 1) describe OT-1 cell killing  
of SIINFEKL-B16 cells in collagen-fibrin gels?
The  experiments  reported  in  Fig.  2,  and  in  experiments 
which were not depicted, indicate that the CTC required to 
control  growth  of  SIINFEKL-B16  cells  in  collagen-fibrin 
gels is 3–4 × 105 OT-1 cells/ml of gel. By definition (Li   
et al., 2002, 2004), the CTC = g/k (Eq. 2). We calculate that g, 
the growth rate of SIINFEKL-B16 cells in collagen-fibrin 
gels (Figs. 1 and 2), is 2.84 × 104 per min. Using this value 
of g and the experimentally determined value for the critical 
OT-1 cell concentration in collagen-fibrin gels of 3.5 × 105 
OT-1 cells/ml, we solved Eq. 2, for k, the rate constant for 
effector cell killing of target cells, and obtained a value of   
8.1 × 1010 ml/OT-1 cell/min. We also calculated k using 
Eq. 1 (Li et al., 2004 and Materials and methods) and values 
of bt, b0, g, and t from experiments described in Figs. 2 and 6, 
and obtained a mean value for k of 8.19 × 1010 ml/OT-1 cell/
min. Substituting k = 8.1 ×  1010 ml/OT-1 cell/min into 
Eq. 1, we compared the experimentally determined and cal-
culated values for OT-1 cell killing of SIINFEKL-B16 cells 
in collagen-fibrin gels (Fig. 6). The Pearson correlation coef-
ficient for the curves described by these datasets (Fig. 6) is 
0.994 (P = 0.000483; R2 = 0.989), which indicates that Eq. 1 
accurately describes OT-1 cell killing of SIINFEKL-B16 cells 
in collagen-fibrin gels.
spheroids (80%). Light microscopy of sections of gels contain-
ing similar concentrations of OT-1 cells and SIINFEKL-B16 
spheroids showed OT-1 cells clustered around and invading 
spheroids. Similarly, Joseph-Pietras et al. (2006) noted human 
monocyte invasion of B16 cell spheroids when the two cell 
types were co-cultured for 38–62 h. Thus, there was no evi-
dence that multilayering of B16 cells in spheroids, or the 
matrix proteins associated with them (Dewever et al., 2007), 
affected OT-1 cell penetration of spheroids or their capacity 
to kill SIINFEKL-B16 cells in spheroids.
OT-1 cells kill SIINFEKL-B16 cells at a constant exponential 
rate and produce sterilizing immunity in collagen-fibrin gels
The most stringent test of the efficacy of cellular immuno-
therapy of tumors is eradication of all tumor cells. Therefore, 
we examined whether OT-1 cells generate sterilizing immu-
nity in vitro. Co-incubation of 106/ml activated OT-1 cells 
with 5 × 105/ml SIINFEKL-B16 cells in collagen-fibrin gels 
for 3 d resulted in recovery of 92% fewer B16 cells than gels 
containing B16 cells alone (Fig. 5). The B16 cells resumed 
growth thereafter, surpassing the initial inoculum of 5 × 105 
B16 cells/ml of gel by day 5. In contrast, 107 activated OT-1 
cells/ml coincubated with 5 × 105 SIINFEKL-B16 cells/ml 
in collagen-fibrin gels killed the B16 cells at a constant expo-
nential rate (99.9%/d) for 5 d, killing 100% of the B16 in-
oculum over this period (Fig. 5). Under these conditions, 
100% of B16 cells were killed. Gels harvested on days 6 and 7 
also yielded no viable B16 cells (unpublished data).
Human and mouse melanomas are reported to contain 
107–108 tumor cells/ml or /g of tumor (Stephens and Peacock, 
1978; Hemstreet et al., 1980; Daugherty et al., 1981; Whiteside 
et al., 1986). To determine whether activated OT-1 cells are 
capable of eradicating SIINFEKL-B16 cells growing in collagen-
fibrin gels at concentrations in this range, we coincubated 
2 × 107 SIINFEKL-B16 cells/ml and 107 OT-1 cells/ml col-
lagen-fibrin gel for 7 d. (B16 cells at >2 × 107/ml lysed the 
collagen-fibrin gels and could not be tested.) To assure that the 
OT-1 cells remained viable and active throughout this pe-
riod, we supplemented the medium with IL-2. No viable 
B16 cells were recovered on day 7 (Fig. 5).
We draw three conclusions from these experiments. First, 
the finding that OT-1 cells kill SIINFEKL-B16 cells at a con-
stant exponential rate (99.3–99.9%/d) for 5–7 d (Fig. 5) 
provides independent confirmation that killing of SIINFEKL-
B16 cells depends strictly on OT-1 cell concentration (Fig. 5). 
Were this not so, the killing rate would change as the target 
cell concentration declined. Second, it indicates that the con-
centration of cytolytically active effector cells remained con-
stant for 5 d in the absence of added IL-2 and for 7 d in its 
presence. Were this not so, the rate of target cell killing would 
change as the concentration of effector cells declined. Third, 
it demonstrates that 107 OT-1 cells/ml produce sterilizing im-
munity versus 2 × 107 SIINFEKL-B16 cells/ml, a concentration 
of melanoma cells within the range found in human melano-
mas in vivo (Stephens and Peacock, 1978; Hemstreet et al., 
1980; Daugherty et al., 1981; Whiteside et al., 1986).
Figure 5.  OT-1 cells affect sterilizing immunity versus SIINFEKL-
B16 cells in collagen-fibrin gels. Collagen-fibrin gels containing 5 × 
105 SIINFEKL-B16 cells/ml of gel alone () or with 106 () or 107 ()/ml 
OT-1 cells were incubated at 37°C for up to 5 d. Gels were lysed on the 
day indicated and assayed for viable B16 cells as described in Materials 
and methods. Data shown represent mean ± SEM of n = 3 experiments 
performed in duplicate. Collagen-fibrin gels containing 2 × 107 SIINFEKL-
B16 cells/ml of gel in medium containing 20 U IL-2/ml of gel alone () or 
with 107 ()/ml OT-1cells were incubated at 37°C for up to 7 d, lysed, and 
assayed for viable B16 cells as described in Materials and methods. Shown 
are the results of a representative experiment performed in duplicate.JEM VOL. 207, January 18, 2010 
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Table S4). Petersen et al. (2006) also reported the intratu-
moral concentration of OT-1 cells/g of tumor on days 3, 5, 
and 7. We have used these values, and those for ova-B16 tu-
mor growth and regression, to calculate k and CTC (Fig. 7 
and Table S4).
The growth rate of ova-B16 cell tumors slowed between 
the day of OT-1 cell administration (day 0) and day 3 (Fig. 7). 
However, tumor regression, as measured by a reduction in 
tumor volume and, therefore, in the total number of ova-
B16 cells in these tumors, did not begin until day 3. It then 
proceeded at a constant rate through day 7. Note that the in-
tratumoral OT-1 cell concentration averaged 1.5 × 106/g of 
tumor between days 0 and 3, was 3 × 106/g of tumor on day 
3, peaked at 5 × 106/g of tumor on day 5, and declined to 
3 × 106/g by day 7. Inspection of Fig. 7 shows that the CTC, 
the OT-1 concentration at which the rate of killing of ova-
B16 cells exactly matched the rate of ova-B16 cell growth, 
was 3 × 106 OT-1 cells/g of tumor and that so long as the 
intratumoral OT-1 concentration remained above the CTC 
Does Eq. 1 describe CD8+ T cell cytolytic activity in vivo?
Regoes et al. (2007) derived an equation similar to Eq. 1 to 
model killing of lymphocytic choriomeningitis virus (LCMV)–
infected splenocytes by LCMV-specific CD8+ T cells in mouse 
spleen in vivo. Using Eq. 1 and the findings of Regoes et al. 
(2007) that LCMV-immune mouse spleen contains 5 × 106 
LCMV-specific CD8+ T cells and that these T cells kill 99.994% 
of LCMV peptide–pulsed target cells in 240 min, we calcu-
lated k for LCMV-specific CD8+ T cell killing. It is 6.4 × 1010 
ml/LCMV-specific CD8+ T cell/min, a value very similar to 
that observed for OT-1 cell killing of SIINFEKL-B16 cells   
in collagen-fibrin gels. Note that Regoes et al. (2007) used 
nongrowing splenocytes as target cells in their experiments. 
Therefore, g = 0. For this reason, we could not calculate a CTC 
for LCMV-specific CD8+ T cell–mediated killing of LCMV 
peptide-pulsed splenocytes. Thus, Eq.1 describes CD8+ 
T cell killing of cognate antigen-expressing target cells in vitro 
and in vivo.
Comparison of the rates at which OT-1 cells kill SIINFEKL-
B16 cells in collagen-fibrin gels in vitro and ova peptide–
expressing B16 cells in tumors in vivo
Petersen et al. (2006) studied the effect of i.p. administration 
of in vitro–activated OT-1 cells on growth/regression of es-
tablished (8 d old, 90.5 mm3 mean vol) ova-B16 cell tumors. 
They reported the mean volume of these ova-B16 tumors in 
control (untreated) and in OT-1 cell–treated mice on days 3, 
5, and 7 after OT-1 cell administration (Fig. 7). B16 tumors 
contain 3 × 105 B16 cells/mm3 (Stephens and Peacock, 1978). 
We used this value to calculate the number of ova-B16 cells 
in tumors of control and OT-1 cell–treated mice (Fig. 7 and 
Figure 6.  Comparison of experimentally derived versus calculated 
values for OT-1 cell killing of SIINFEKL-B16 cells in collagen-fibrin 
gels. Experimental data ±SEM are from Fig. 2 and Table S1. Calculated 
values were determined using Eq. 1 (Li et al., 2004), and k = 8.1 × 1010 
ml/OT-1 cell/min. Pearson’s correlation between experimental and calcu-
lated values = 0.994 (P = 0.00048).
Figure 7.  Relationship between ova-B16 tumor growth/regression 
and intratumoral OT-1 cell concentration in OT-1 cell–treated ova-
B16 tumor–bearing mice. Data are obtained from Figs. 2 and 4 in  
Petersen et al. (2006) and were calculated as described in Table S4. C57BL/6 
mice were inoculated with 5 × 105 ova-B16 cells subcutaneously on day 
8, and with 20 × 106 in vitro–activated OT-1 cells i.p. on day 0. Intratu-
moral concentration is shown of OT-1 cells () from Fig. 2 (Petersen et al., 
2006). Also shown are the number of ova-B16 cells in tumors of control 
mice () and in tumors of mice that received 20 × 106 in vitro–activated 
OT-1 cells on day 0 () calculated from Fig. 4 of Petersen et al. (2006) as 
described in (Table S4). CTC () was calculated as described in Li et al. 
(2004) and in the Materials and methods (Table S4). Dashed lines repre-
sent extrapolated trends based on findings reported in Petersen et al. 
(2006) and Stephens and Peacock (1978). The vertical dashed-dotted line 
indicates the point in time at which the intratumoral OT-1 concentration 
exceeds the CTC. The vertical dotted line indicates the estimated point in 
time at which the intratumoral OT-1 concentration falls below the CTC, 
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applicable to CD8+ T cell–mediated control of tumor cell 
growth and viral infection in vivo (Fig. 7 and Fig. 8) Third, 
by use of Eq. 1 it is possible to calculate and compare the 
efficiency (k) with which antigen-specific CD8+  T cells kill 
cognate antigen–expressing target cells in vitro and in various 
tissue compartments in vivo. Fourth, by use of Eq. 2 it is pos-
sible to calculate the critical concentration of antigen-specific 
CD8+ T cells under all conditions examined in vivo and in 
vitro. Fifth, by determining the rate of tumor regression, or 
the rate of clearance of virus-infected cells, and the time 
period during which the intratumoral or intralesional con-
centration of tumor or viral antigen-specific CD8+ T cells 
remains above the CTC, it is possible to predict whether the 
tumor or virus infection will be eradicated or recrudesce.
DISCUSSION
These results enable us to define three principles that, in 
combination with Eqs. 1 and 2, provide a quantitative frame-
work for describing CD8+ T cell–mediated host defense versus 
viral and intracellular bacterial pathogens and for cellular 
immunotherapy. First, the concentration of activated antigen-
specific CD8+ T cells determines the efficiency with which 
these cells kill cognate antigen-expressing target cells under all 
conditions examined. Second, Eq.1 (Li et al., 2004) describes 
CD8+ T cell killing of cognate antigen-expressing target cells 
in vitro and in vivo. Third, a critical concentration of antigen-
specific CD8+ T cells is required to control growth of cognate 
antigen–expressing transformed cells in collagen gels in vitro 
and in mouse subcutaneous tissue in vivo, and of polyoma 
virus in mouse splenocytes in vivo.
(i.e., 3 × 106 OT-1 cells/g of tumor), tumors regressed. Fig. 7 
also shows that when the intratumoral OT-1 cell concentra-
tion declines to less than the CTC (i.e., on days 8 or 9), tumor 
growth will resume. Indeed, this is consistent with the obser-
vations of Petersen et al. (2006).
To determine whether the CTC calculated using values 
of g and k obtained using Eq. 1 fits the findings of Petersen 
et al. (2006; Fig. 7), we used their data (Table S4) for g, t, and 
intratumoral OT-1 cell concentration for each of the three 
time intervals (days 0–3, 3–5, and 5–7) described in the previ-
ous paragraph to calculate the CTC. We obtained mean val-
ues for g and k of 2.7 × 104/min and 8.9 × 1011 ml/OT-1 
cell/min, respectively, for the three time intervals, yielding a 
mean CTC (g/k) of 2.93 × 106 OT-1 cells/g ova-B16 tumor. 
The values of g for ova-B16 cell growth in control mice 
(Table S4) were within the range of values we obtained for 
growth of B16 cells in collagen-fibrin gels in vitro (Fig. 1) 
and those reported by Li et al. (1984) for B16 cell growth in 
tumors in vivo. In contrast, the values of k and CTC for OT-1 
cell killing of ova-B16 cells in vivo were approximately nine-
fold smaller and eightfold larger, respectively, than comparable 
values for OT-1 cell killing of SIINFEKL-B16 cells in collagen-
fibrin gels in vitro, indicating that OT-1 cells kill ova-B16 
cells less efficiently in tumors in vivo than in collagen-fibrin 
gels in vitro.
We made similar calculations using data from the study by   
Lukacher et al. (1999) of polyoma virus antigen–specific CD8+ 
T cell–mediated killing of polyoma virus–infected splenocytes 
in spleens of immunocompetent mice. We found mean values 
of k and CTC of 5.7 × 1011 ml/polyoma virus antigen–specific 
CD8+ T cell/min and 4.8 × 106 polyoma virus antigen–specific 
CD8+ T cells/ml, respectively (Fig. 8 and Table S5). The value 
of k for polyoma virus antigen–specific CD8+ T cell–mediated 
killing of polyoma virus–infected splenocytes is 14-fold smaller 
than that calculated for OT-1 cell killing of ova-B16 cells in 
collagen-fibrin gels in vitro and for LCMV antigen–specific 
CD8+ T cell killing of LCMV peptide–pulsed splenocytes in 
spleen (Regoes et al., 2007).
As observed for OT-1 cell killing of ova-B16 cells in 
vivo, elimination of polyoma virus–infected cells did not begin 
until the concentration of polyoma antigen–specific CD8+ 
T cells was at or above the critical concentration of 4.8 × 106 
polyoma virus antigen–specific CD8+ T cells/ml or /g of spleen 
(Fig. 7 and Table S5). Moreover, in contrast to the situation 
described after administration of OT-1 cells to ova-B16 cell 
tumor-bearing mice (Fig. 7), the concentration of polyoma 
virus antigen–specific CD8+ T cells/ml or /g of spleen remained 
well above the CTC for many days after the concentration of 
polyoma virus had fallen to undetectable levels. Lukacher et al. 
(1999) reported that the persistence of polyoma virus antigen–
specific CD8+ T cells above CTC resulted in sterilizing immu-
nity versus polyoma virus.
We draw five conclusions from these findings. First, Eq. 1 
accurately models killing of antigen-expressing tumor cells 
and virus-infected splenocytes by cognate antigen–specific 
CD8+ T cells. Second, the critical concentration concept is 
Figure 8.  Effect of polyoma antigen–specific CD8+ T cells on poly-
oma virus growth in splenocytes from mice inoculated subcutane-
ously on day 0 with 2 × 106 PFU of virus. Data are obtained from Fig. 2 
and Table I in Lukacher et al. (1999). Polyoma virus concentration (, PFU/
mg of spleen). Intrasplenic concentration of polyoma antigen–specific 
CD8+ T cells/ml of spleen () was calculated as reported in Table S5. k and 
CTC were calculated using Eqs. 1 and 2 (Li et al., 2004), respectively, as 
described in Table S5 and in Materials and methods.JEM VOL. 207, January 18, 2010 
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in both the in vitro (Fig. 2) and in vivo (Fig. 7 and Table S4) 
situations, the OT-1 cells were activated in vitro under simi-
lar conditions. This 9- to 14-fold difference in k values also 
is matched by a 10-fold difference in CTC. What accounts 
for these large differences in k and CTC in collagen-fibrin 
gels versus in tumors and in polyoma virus–infected spleen 
in vivo?
In the case of OT-1 cell killing of ova-B16 cells in tumors 
and of polyoma antigen–specific CD8+ T cell killing of poly-
oma virus–infected splenocytes in spleen, immunomodulatory 
activities elicited by the tumor and by viral infection may have 
altered the tissue environment, thereby reducing the killing 
efficiency of the antigen-specific CD8+ T cells. In the case of 
tumors (Whiteside et al., 1986; Bronte and Mocellin, 2009) 
and of chronic viral infections (Virgin et al., 2009), such 
immunomodulatory activities are well known. To our knowl-
edge, there is no corresponding information about the extent 
to which the intrasplenic environment is modified by acute 
viral infection (e.g., polyoma virus [Fig. 8]). Nonetheless, it is 
likely that immunomodulatory factors (e.g., T cell suppressive 
factors) account for the 9- to 14-fold difference in CTC 
observed in collagen-fibrin gels in vitro versus tumors and 
acute intrasplenic viral infections in vivo, respectively.
Spleen and tumors contain macrophages, dendritic cells, 
regulatory and effector T cells, fibroblasts, and endothelial cells, 
most of which have the capacity to produce proinflammatory 
(e.g., TNF and IL-12) and antiinflammatory (e.g., TGF- 
and IL-10) substances and extracellular matrix components. 
In contrast, collagen-fibrin gels lack these stromal cells and 
their soluble and insoluble (e.g., matrix proteins) secretory 
products. This is a positive attribute of these gels in the sense 
that it enables investigators to compare the cytolytic activity 
of antigen-specific CD8+ T cells versus cognate antigen–
expressing target cells in a three-dimensional matrix devoid 
of stromal cells and stromal cell secretory products with the 
cytolytic activity of the same CD8+ T cells versus the same 
target cells expressing the same antigens in tissues containing 
stromal cells and their secretory products. Investigators also 
can form gels containing antigen-specific CD8+ T cells, peptide-
pulsed target cells, and one or more of these stromal cells 
and/or secretory products and assess their effects, individually 
and collectively, on the cytolytic activity of CD8+ T cells. By 
these means, it may be possible to replicate in vitro the pro- 
and  antiinflammatory  environments  of  infected,  inflamed, 
and tumor-bearing tissues. Thus, what might at first be per-
ceived as a negative attribute of collagen-fibrin gels could be 
one of their greatest assets.
Implications of these findings for cellular immunotherapy  
of cancer
The findings reported here have obvious relevance for cellu-
lar immunotherapy of melanoma and perhaps other tumors. 
Cellular immunotherapy produces objective melanoma re-
gression in >50% of patients yet cures a very small percentage 
of them (Dudley et al., 2002; Dudley and Rosenberg, 2003). 
This paper suggests at least one reason for this disconnect 
Collagen-fibrin gels
Melanomas originate in the epidermis but invade and grow 
in the dermis before spreading to other organs. The concen-
trations of collagen I and fibrinogen used to form the gels 
used in these experiments are in the range of those prevailing 
in carcinomas in rodent dermis and in normal human dermis 
(Grabowska, 1959; Dvorak et al., 1992; Dewever et al., 2007). 
The concentration of serum proteins in the medium bathing 
these gels is 20% of that found in extracellular fluids from 
human skin (Takeda and Chen, 1967; Le et al., 1998; Svedman 
et al., 2002). Thus, the gels in which activated OT-1 and 
SIINFEKL-B16 cells were co-cultured contain similar concen-
trations of collagen and fibrin, but lower concentrations of 
serum proteins, than those found in tumors, in rodent der-
mis, and in human dermis in vivo.
Clonogenic assay
In combination with the collagen-fibrin gel system described 
in this paper, the clonogenic assay used to measure the number 
of viable B16 melanoma cells is 4,500–5,500-fold more sensi-
tive than the packed cell pellet–type assays generally used to 
measure CD8+ T cell cytocidal activity in vitro (Fig. 4 B). 
These methods enable us to distinguish 99.99 versus 99.9999% 
tumor cell killing and sterilizing immunity. Using this system, 
we demonstrate that at a concentration of ≥107/ml of gel, 
OT-1 cells produce sterilizing immunity versus 2 × 107/ml 
SIINFEKL-B16 melanoma cells in 7 d (Fig. 5), a concentra-
tion of B16 cells which is at the lower range of tumor cells in 
human melanomas in vivo (Whiteside et al., 1986). We are 
certain that all clonogenic B16 cells were killed because the 
clonogenic assay used is capable of detecting a single clono-
genic B16 cell, and because cultures harvested on subsequent 
days (Fig. 5) yielded no viable B16 cells. To our knowledge, 
this is the first identification of the concentration of antigen-
specific CD8+ T cells required to kill 100% of tumor cells 
growing at a concentration similar to that found in tumors. 
As Blattman and Greenberg (2006) note, in cancer therapy, 
the difference between mostly dead and all dead is a life and 
death distinction.
Relationship between antigen-specific CD8+ T cell killing  
of target cells expressing a cognate antigen in collagen-
fibrin gels in vitro and in melanomas in vivo
The value of k for OT-1 cell killing of SIINFEKL-B16 cells 
in collagen-fibrin gels (8.1 × 1010 ml/OT-1 cell/min) is very 
similar to that for LCMV antigen-specific CD8+ T cell killing 
of  LCMV  peptide–pulsed  splenocytes  in  mouse  spleen  in 
vivo (6.4 × 1010 ml/LCMV antigen-specific CD8+ T cell/min). 
In contrast, the values of k for OT-1 cell killing of ova-B16 
cells in melanomas in vivo (8.9 × 1011 ml/OT-1 cell/min) 
and for polyoma virus antigen–specific CD8+ T cell killing of 
polyoma virus–infected splenocytes in spleen in vivo (5.7 × 
1011 ml/polyoma virus–specific CD8+ T cell/min) are 9- 
and 14-fold smaller than those for OT-1 cell killing of   
SIINFEKL-B16 cells in collagen-fibrin gels. In the case of 
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cells. Indeed, we have identified OT-1 cell activation protocols 
that more than double their efficiency in killing SIINFEKL-
B16 cells in collagen-fibrin gels (unpublished data). Fourth, 
we have assumed that the tumor vasculature of all melanomas 
is equally efficient in delivering CD8+ T cells to the tumor 
parenchyma. Buckanovich et al. (2008) have shown that the 
efficiency of this process can be increased by >10-fold. For all 
of the reasons stated here, it is important to determine the ef-
ficiency of entry of ex vivo–expanded CD8+ T cells into 
tumor beds, their residence time in the tumor bed, and their 
cytolytic activity under both ideal (e.g., collagen-fibrin gels) 
and in vivo conditions.
The studies reported in this paper identify three parame-
ters that appear to be especially important for understanding 
the  therapeutic  potential  of  cellular  immunotherapy.  The 
first is the concentration of all cytolytic effector cells deliv-
ered to, and active within, tumors. The second is the killing 
efficiencies (k) of all effector cells, singly and in combination, 
within the tumor bed. The third is the length of time each of 
these effector cells remains cytolytically active within the 
tumor bed. Information about these parameters will enable 
investigators to assess whether the high frequency of objective 
tumor regression, but low frequency of cure, observed in 
melanoma patients treated with ex vivo–activated CD8+ T 
cells is a consequence of delivery of an insufficient number of 
tumor antigen–specific CD8+ T cells to tumors to raise the 
intratumoral concentration to 30-fold above the CTC (Fig. 5), 
or of deleterious effects of the tumor environment on the 
viability and/or effector functions of CD8+ T cells. Studies in 
progress show that the collagen-fibrin gel system described in 
this paper is also useful for assessing killing by cloned tumor 
antigen–specific human CD8+ T cells of human melanoma 
cells expressing a cognate antigen (unpublished data).
Other applications of Eq. 1
Our findings with respect to CD8+ T cell killing of nongrow-
ing  B16  cells  (Table  S1)  may  be  relevant  to  studying  and   
understanding host defense versus viruses and intracellular bac-
terial pathogens and rejection of organ transplants. With re-
spect to microbial pathogens, it will be useful to determine the 
CTC for antigen-specific CD8+ T cells to control infection in 
various tissues. Assuming OT-1 cells are representative of the 
majority of antigen-specific CD8+ T cells, the results reported 
in this paper and by Snyder et al. (2003) that only 2–4% of 
these cells are cytolytically active suggest that viral and bacterial 
antigen–specific CD8+ T cells control infections largely by se-
creting IFN- and TNF and that CD8+ T cells use their cyto-
lytic effector activity more sparingly than previously assumed.
With respect to the effects of host CD8+ T cells on allo-
geneic transplants, we suggest that such transplants remain 
functional so long as they contain sufficient stem cells to re-
place differentiated cells at a rate equal to the rate of differen-
tiated cell killing by CD8+ T cells. However, if CD8+ T cells 
kill the organ’s differentiated cells at a faster rate than can be 
replaced by the organ’s stem cells, or if CD8+ T cells attack 
the organ’s stem cells themselves, the organ is likely to fail. 
between response and cure: it is the failure to deliver and 
maintain a sufficient intratumoral concentration of tumor 
antigen–specific CD8+ T cells/ml of tumor for a sufficient time 
period to kill 100% of clonogenic tumor cells (Figs. 5 and 7). 
The studies reported in this paper provide quantitative infor-
mation regarding these parameters. They show that a con-
centration of ≥107 activated OT-1 cells/ml is required to kill 
100% of SIINFEKL-B16 cells/ml collagen-fibrin gel in 7 d 
(Fig. 5). In these gels, target cell cytolysis depends only on the 
CD8+ T cell concentration (Figs. 2, 5, and 7). Accordingly, 
assuming melanomas contain 3 × 108 melanoma cells/ml or /g 
of tumor (Stephens and Peacock, 1978), and that melanoma 
antigen–specific CD8+ T cells kill melanoma cells in vivo at 
the same rate as the OT-1 cells used in the experiments shown 
in Fig. 5, delivery and maintenance of ≥107 melanoma antigen-
specific CD8+ T cells/g melanoma for ≥8 d should result in 
eradication of the melanoma. However, our analysis of the 
findings of Petersen et al. (2006; Fig. 7 and Table S4) shows 
that OT-1 cells kill ova-B16 cells at an approximately nine-
fold lower rate (k) and have an approximately eightfold higher 
CTC in tumors in vivo than in collagen-fibrin gels. Under 
these circumstances, delivery and maintenance of ≥108 mela-
noma antigen-specific CD8+ T cells/ml or /g melanoma for ≥8 
d would be required to effect tumor eradication. This is a very 
high threshold and one that does not bode well for success in 
cellular immunotherapy of cancer. Nonetheless, in a small num-
ber of cases cellular immunotherapy has been demonstrated to 
be curative (Dudley et al., 2002), suggesting that in vivo there 
are other factors that, under certain circumstances, contribute to 
the efficacy of antigen-specific CD8+ T cells. We describe four 
of these factors in the subsequent paragraph.
First, our calculations regarding the concentration of tumor 
antigen–specific CD8+ T cells that must accumulate in a 
tumor bed to effect tumor eradication assumes that these CD8+ 
T cells are the sole cytolytic effectors. However, the presence 
of activated tumor antigen–specific CD8+ T cells within the 
tumor bed may promote accumulation and tumor cell killing 
by other cytolytic effector cells (e.g., NK cells and activated 
macrophages). Under these conditions, CD8+ T cells may be 
only one of several cytolytically active effector cells at work 
within the tumor. Therefore, our calculations may underesti-
mate the total cytocidal activity of all effector leukocytes that 
assemble in a tumor in response to signals initiated by tumor 
antigen-specific CD8+ T cells and or tumor cell cytolysis. 
Second, our calculations assume that tumor cell killing by 
clones of CD8+ T cells whose TCRs recognize different 
tumor antigens is merely additive. It is possible it is multiplica-
tive. If so, the intratumoral presence of 3 × 106 CD8+ T cells 
versus putative tumor antigen A, 3 × 106 CD8+ T cells versus 
putative tumor antigen B, and 3 × 106 CD8+ T cells versus 
putative tumor antigen C could result in a 27-fold increase in 
tumor cell killing. Third, our calculations assume that all CD8+ 
T cells kill with the same efficiency as OT-1 cells. CD8+ T cells 
vary widely in their killing efficiencies (Stuge, et al., 2004). 
Accordingly, it may be possible to produce CD8+ T cell pop-
ulations that kill at a higher rate than that observed for OT-1 JEM VOL. 207, January 18, 2010 
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48-well plate. At indicated times, medium overlying each gel was removed 
and gels were dissolved by overlaying each gel with 100 µl PBS containing   
2.5 mg/ml collagenase type 1A for 20 min at 37°C, followed by further addition 
of 100 µl PBS containing 2.5 mg/ml trypsin for another 20 min at 37°C. 
The resulting solution containing cells and dissolved gel components was di-
luted 10–1,000-fold (depending on the initial B16 cell concentration in the 
gel) in OT-1 growth medium and 100-µl aliquots of the final dilution were 
plated in each of two 60 × 15-mm tissue culture dishes containing 2 ml   
OT-1 growth medium. The dishes were incubated at 37°C for 7 d in a 95% 
air/5% CO2 humidified atmosphere to allow B16 cells to form macroscopic 
colonies, washed with PBS, treated with 2 ml of 3.7% formaldehyde in PBS 
for 15 min to fix the B16 cells, washed again with PBS, incubated for 2 h in 
2 ml of 4% wt/vol methylene blue in H2O at room temperature, washed 
with distilled water to remove excess methylene blue, dried, and the blue-
stained colonies counted manually as previously described (Freedman et al., 
1984). Control experiments showed that B16 cells had a plating efficiency of 
60% regardless of whether they were released from plastic tissue culture 
plates with EDTA or from collagen-fibrin gels with collagenase and trypsin 
and/or plated in -ME–containing medium. Thus, the number of B16 cells 
reported as placed into fibrin-collagen I gels is 1.66-fold the number of 
cells recovered from them.
Cell sizes and volumes. Activated OT-1 cells are 7 µm in diameter as mea-
sured by phase-contrast microcopy of unfixed cells. Packed cell volumes of B16 
cells, activated OT-1 cells, and naive splenocytes from wild-type C57BL/6 
spleen were determined by centrifuging 104 B16 cells, 104 OT-1 cells, or 104 
splenocytes in 20 µl OT-1 medium for 2 min at 200 g in 25-µl glass micropi-
pettes (sealed at one end). The volumes of each cell type, calculated by dividing 
the packed cell volume by the number of cells in the pipette, were 2.5 × 103 
nl/B16 cell (4 × 108 B16 cells/ml), 1.7 × 104 nl/activated OT-1 cell (5.9 × 109 
OT-1 cells/ml), and 2.2 × 104 nl/splenocytes (4.5 × 109 splenocytes/ml).
Packed cell pellet–type assays. Wells of a 96-well round-bottom tissue 
culture plate were each filled with 0.2 ml OT-1 medium containing 104 B16 
cells, pulsed previously with 106 M SIINKFEKL peptide, and the number 
of activated OT-1 cells required to produce the ratios of OT-1/B16 cells in-
dicated in the figures. The plate was centrifuged at 1,000 rpm (200 g) for 
5 min to pellet cells and then incubated at 37°C in a humidified incubator 
for 4 h. The medium was removed and the pellet was disaggregated by incu-
bation in 0.1 ml of PBS containing 5 mM EDTA for 5 min at 37°C. The so-
lution was diluted 100-fold in OT-1 growth medium and 0.1-ml aliquots of 
the final dilution were plated for colony formation as described in Clono-
genic assay for B16. In some experiments, naive splenocytes (filler cells) from 
wild-type C57BL/6 mice were added to vary the ratio of OT-1 to B16 cells 
while keeping total cell volume constant.
CFSE labeling of OT-1 cells. 106–107 OT-1 cells were incubated in 1 ml 
PBS containing 0.1% glucose, 0.1% BSA (PBS-G-BSA), and 10 µM CFSE at 
37°C for 15 min, washed three times with 1 ml OT-1 medium, resuspended 
at a concentration of 106 cells/ml in OT-1 medium, and co-embedded in 
collagen-fibrin gels with B16 cells at the indicated concentrations. Gels were 
overlaid with 1 ml OT-1 medium ± 100 U/ml IL-2 and incubated at 37°C 
in a 95% air/5% CO2 humidified atmosphere. 24, 48, and 72 h later, the gels 
were digested with collagenase and trypsin and the released cells were washed 
with PBS-G-BSA and divided into two aliquots. The cells in the first aliquot 
were incubated with 1.5 µM propidium iodide in PBS-G-BSA for 10 min, 
washed with PBS-G-BSA, and the number and fluorescence of viable CFSE-
labeled OT-1 cells was assessed with a FACSCalibur (BD). The second ali-
quot was assayed as described in Clonogenic assay for B16.
Frozen  sections.  Collagen-fibrin  gels  containing  SIINFEKL-B16  cells 
were formed, as described in Formation of collagen-I–fibrin gels..., in 8-µm 
pore cell culture inserts seated in wells containing 1 ml OT-1 medium in 
24-well tissue culture plates (BD) and overlaid with 0.5 ml OT-1 medium, 
and they were incubated at 37°C in a 95% air/5% CO2 atmosphere. 24, 72 
and 120 h after forming the gels, the medium overlying the gels was   
The collagen-fibrin gel system described here may be useful 
for investigating these possibilities in vitro.
MATERIALS AND METHODS
Materials. Human fibrinogen was obtained from American Diagnostica 
Inc., collagen I, cell culture inserts and tissue culture plates from BD, SIIN-
FEKL peptide (OVA 257–264) from American Peptide Company, CFSE 
from Invitrogen, and recombinant mouse IL-2 from Millipore. All other re-
agents were purchased from Sigma-Aldrich. All experiments using mice 
were Institutional Review Board approved by Columbia University.
Cells. B16 melanoma cells (vol. = 2,757 µm3 assuming spherical diameter = 
17.4 µm [Ochalek, et al., 1988]; H2-Kb [Hu and Lesney, 1964]), were main-
tained as monolayer cultures in RPMI 1640 medium supplemented with 
10% FBS and 50 µM -ME (OT-1 growth medium) at 37°C in a 95% 
air/5% CO2 humidified atmosphere, detached by incubation at 37°C for 
5 min in PBS containing 5 mM EDTA, pelleted by centrifugation (400 g for 
10 min), and resuspended at 106 cells/ml in OT-1 growth medium. Where 
indicated, B16 cells were incubated in suspension at 106 cells/ml in RPMI 
medium containing 1 µM SIINFEKL peptide (ovalbumin residues 257–264) 
for 2 h at 37°C, washed three times in PBS, and resuspended in OT-1 
growth medium. B16 spheroids were sedimented at 1 g through a cushion of 
FBS to separate them from single B16 cells. The purified spheroids were 
pulsed with 1 µM SIINFEKL for 2 h and a measured aliquot of this prepara-
tion was disaggregated by trituration in EDTA/0.05% trypsin buffer, releas-
ing >95% of cells from the spheroids. The number of released B16 cells was 
assessed by counting cells in a hemocytometer.
OT-1 CD8+ T cells, harvested from spleens of C57BL/6 mice, express 
a transgene encoding a TCR that specifically recognizes SIINFEKL peptide 
bound to MHC-I H-2kb (Hogquist et al., 1994). Activated OT-1 T cells 
were  generated  by  incubation  of  5  ×  106/ml  OT-1  SIINFEKL-pulsed 
mouse splenocytes in vitro for 5–7 d in the presence of IL-2 (Moore et al., 
1988; Curtsinger et al., 1998). In brief, an OT-1 mouse spleen was homoge-
nized, the released cells were pelleted and resuspended in 5 ml ACK buffer 
(0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM EDTA) for 1 min to lyse red 
blood cells, and the splenocytes were pelleted, washed, resuspended at 5 × 
106 cells/ml in OT-1 growth medium containing 0.75 µg/ml SIINFEKL 
peptide, and incubated at 37°C in a 95% air/5% CO2 humidified atmo-
sphere. On days 3 and 5, 25 ml of fresh OT-1 growth medium containing 
10 U/ml of mouse recombinant IL-2 was added to the cultures. On day 7, 
the cells were harvested and OT-1 cells were purified by centrifugation at 
400 g for 30 min at room temperature over a Histopaque gradient (density = 
1.083). Cells isolated by this method were incubated with PE-labeled anti-
CD8 or FITC-labeled anti-V5 monoclonal antibodies, washed, and as-
sayed by FACS (BD). Over 90% were CD8+ and V5+.
Formation of collagen-I–fibrin gels containing B16 and OT-1 cells. 
Each well of a 48-well tissue culture plate was filled sequentially with 5 µl 
PBS containing 0.1 U thrombin, 100 µl PBS containing 1 mg/ml of human 
fibrinogen, 1 mg/ml of rat tail collagen I, 10% FBS, and 103–2 × 106  
SIINFEKL peptide-pulsed B16 cells (SIINFEKL-B16 cells), with or without 
103–106 OT-1 cells. The plates were incubated for 15 min at 37°C in a 95% 
air/5% CO2 humidified atmosphere to allow the fibrin to gel. In some early   
experiments, 10 µl of 107 M d-phenylalanyl-l-propyl-l-arginine chloromethyl 
ketone (PPACK) was added to the top of each gel to inhibit thrombin and the 
plates were incubated at 37°C for another 15 min to allow the collagen to gel. 
(Subsequent experiments indicated that this PPACK step was unnecessary and it 
was omitted.) Gels were overlaid with 0.5 ml OT-1 growth medium and incu-
bated at 37°C in a 95% air/5% CO2 humidified atmosphere. These gels are   
0.1 ml in volume and 1,500 µm in height. In preliminary experiments, we 
found that B16 cells incubated in gels composed of fibrin alone dissolved these 
gels in 3–4 d. Addition of collagen I maintained gel integrity for 7–10 d.
Clonogenic assay for B16 cells. SIINFEKL-B16 cells, with or without 
OT-1 cells, were incubated at 37°C in collagen-fibrin gels in wells in a   234 CD8+ T cell–mediated killing of melanoma cells | Budhu et al.
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removed and the inserts were placed in wells containing PBS at room tem-
perature for 15 min to wash away serum proteins, fixed with 10% neutral-
buffered formalin for 1 h at room temperature, washed with PBS, overlaid 
with 0.5 ml of 5% gelatin in PBS at 37°C, and incubated at this temperature 
for 20 min to allow the gelatin solution to permeate the collagen-fibrin gels. 
The inserts then were placed at 4°C for 30 min to allow gelatin to gel. Gelatin-
impregnated gels were mechanically released from inserts using a scalpel, bi-
sected vertically, and incubated in 30% sucrose overnight at 4°C. Each 
half gel was placed in a cryomold and the cryomold was filled with OCT 
embedding medium and placed in a bath of 2-methylbutane and dry ice. 10-
µm-thick frozen sections were cut parallel to the vertically bisected face of 
the gels, and the sections were stained with hematoxylin/eosin and placed 
on glass slides for light microscopy.
Calculations. The value of k (the experimentally determined target cell 
killing constant) was calculated as previously described (Li et al., 2004) using 
Eq. 1 (bt/b0 = e-kpt + gt). bt = experimentally determined target cell concentra-
tion per milliliter of gel or tumor at time t (in minutes) of co-incubation of 
antigen-expressing target cells with antigen-specific CD8+ T cells in colla-
gen-fibrin gels or inoculation of mice with antigen-specific CD8+ T cells. 
b0 = initial target cell concentration per ml gel or tumor. The CD8+ CTC was 
calculated using Eq. 2 (Li et al., 2004; CTC = g/k). g = the experimentally 
determined rate of B16 cell growth in vitro or in vivo or of increase in poly-
oma virus–infected target cells, calculated using the relationship ln bt/b0 = 
g × t (min). We estimated mouse spleen volume and wet weight for LCMV 
infected mice to be 0.15 ml and 0.15 g, respectively, and 0.1 ml and 0.1 g, 
respectively, for polyoma virus–infected mice. B16 melanoma tumors con-
tain 3 × 108 B16 cells/ml or /g of tumor (Stephens and Peacock, 1978).
Statistics. Unless otherwise indicated, all experiments were performed at 
least three times in duplicate. Data are reported as the mean ± SEM for the 
number of experiments indicated.
Online supplemental material. Fig. S1 shows the OT-1 SIINFEKL pep-
tide concentration required for optimal killing of B16 cells in collagen-fibrin 
gels. Fig. S2 shows the killing of SIINFEKL-B16 cells in spheroids versus 
single SIINFEKL-B16 cells by OT-1 cells. Fig. S3 shows that CMA inhibits 
OT-1 cell killing of SIINFEKL-B16 cells. Table S1 shows that activated 
OT-1 cells kill growing and nongrowing SIINFEKL-pulsed B16 cells with 
approximately equal efficiency. Table S2 shows that the addition of naive 
spleen cells had no effect on killing efficiency of OT-1 cells in collagen-fibrin 
gels. Table S3 shows that OT-1 cell concentration determines the efficiency 
of killing of SIINFEKL-B16 cells in packed-cell-pellet type assays. Table S4 
shows OT-1 cell killing of ova-B16 cells in 8-d-old tumors in vivo. Table S5 
shows polyoma virus antigen–specific CD8+ T cell killing of polyoma virus–
infected splenocytes in mouse spleen in vivo. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20091279/DC1.
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